Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Wade

Showing results (581-590 of 601) with videos related to

Pageof 61
Sort By:
Journal of Patient-Reported Outcomes|June 29, 2018
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)Joseph M Unger, Katherine Griffin, Gary W Donaldson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2021
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research StatementEdward S Kim, Thomas S Uldrick, Caroline Schenkel, et al.
The Lancet. Oncology|December 5, 2018
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trialEleftherios P Mamounas, Hanna Bandos, Barry C Lembersky, et al.
Journal of Patient-Reported Outcomes|July 10, 2020
A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013Siu-Fun Wong, Joseph M Unger, James L Wade, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2021
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412Grzegorz S Nowakowski, Fangxin Hong, David W Scott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2020
Neratinib-Plus-Cetuximab in Quadruple-WT (<i>KRAS, NRAS, BRAF, PIK3CA</i>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib StudySamuel A Jacobs, James J Lee, Thomas J George, et al.
JAMA|June 7, 2006
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trialVictor G Vogel, Joseph P Costantino, D Lawrence Wickerham, et al.
Cancer Prevention Research (Philadelphia, Pa.)|April 21, 2010
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancerVictor G Vogel, Joseph P Costantino, D Lawrence Wickerham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2022
A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and NeckCherie-Ann O Nathan, D Neil Hayes, Theodore Karrison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2017
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2Patricia A Ganz, Edward H Romond, Reena S Cecchini, et al.
Pageof 61

Showing results (581-590 of 601) with videos related to

Sort By:
Pageof 61
Journal of Patient-Reported Outcomes|June 29, 2018
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)Joseph M Unger, Katherine Griffin, Gary W Donaldson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2021
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research StatementEdward S Kim, Thomas S Uldrick, Caroline Schenkel, et al.
The Lancet. Oncology|December 5, 2018
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trialEleftherios P Mamounas, Hanna Bandos, Barry C Lembersky, et al.
Journal of Patient-Reported Outcomes|July 10, 2020
A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013Siu-Fun Wong, Joseph M Unger, James L Wade, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2021
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412Grzegorz S Nowakowski, Fangxin Hong, David W Scott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2020
Neratinib-Plus-Cetuximab in Quadruple-WT (<i>KRAS, NRAS, BRAF, PIK3CA</i>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib StudySamuel A Jacobs, James J Lee, Thomas J George, et al.
JAMA|June 7, 2006
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trialVictor G Vogel, Joseph P Costantino, D Lawrence Wickerham, et al.
Cancer Prevention Research (Philadelphia, Pa.)|April 21, 2010
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancerVictor G Vogel, Joseph P Costantino, D Lawrence Wickerham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2022
A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and NeckCherie-Ann O Nathan, D Neil Hayes, Theodore Karrison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2017
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2Patricia A Ganz, Edward H Romond, Reena S Cecchini, et al.
Pageof 61